A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
An HIV antibody achieves potency and breadth by binding simultaneously to two conserved glycans on the viral envelope protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
EMAN2: An extensible image processing suite for electron microscopy
Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.05.009 · Cited by 2,994
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
EMAN: Semiautomated Software for High-Resolution Single-Particle Reconstructions
Ludtke, S. J., Baldwin, P. R., & Chiu, W. (1999) · Journal of Structural Biology · doi:10.1006/jsbi.1999.4174 · Cited by 2,391
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citation
Cited by
Items 201–300 of 709
Bouvin-Pley, M., Morgand, M., Meyer, L., Goujard, C., Moreau, A., Mouquet, H., Nussenzweig, M. C., Pace, C. S., Ho, D. D., Björkman, P. J., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02083-14 · Cited by 57
Self-citationDitse, Z., Muenchhoff, M., Adland, E., Jooste, P., Goulder, P., Moore, P. L., & Morris, L. (2018) · Journal of Virology · doi:10.1128/jvi.00878-18 · Cited by 57
Zolla‐Pazner, S., Edlefsen, P. T., Rolland, M., Kong, X., deCamp, A. C., Gottardo, R., Williams, C. A. U., Tovanabutra, S., Sharpe, S., Mullins, J. I., et al. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.10.022 · Cited by 56
“Both V2 and V3 induce highly cross-reactive Abs in HIVinfected individuals (Gorny et al., 1997, 2012); and V2 and V3 induce both glycan-independent (Gorny et al., 1997, 2002) and glycandependent Abs (Pejchal et al., 2011).”
BackgroundInfluentialMoldt, B., Le, K. M., Carnathan, D. G., Whitney, J. B., Schultz, N., Lewis, M. G., Borducchi, E. N., Smith, K. M., Mackel, J. J., Sweat, S. L., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001102 · Cited by 55
“PGT126 is part of the group of bnAbs that recognizes the high-mannose patch centered around the glycan at position N332 on gp120 [40-42,52,53].”
BackgroundSelf-citationZhang, Y.-N., Paynter, J., Antanasijevic, A., Allen, J. D., Eldad, M., Lee, Y.-Z., Copps, J., Newby, M. L., He, L., Chavez, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37742-z · Cited by 56
“Complex-type glycans can be found at gp120 N88,N185e,N301/N355(althoughhigh-mannosepredominates),N398, N462, and across the N611, N618, and N637 glycans on gp41 (Fig.”
InfluentialSelf-citationA Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein
Sethi, A., Jianhui, T., Derdeyn, C. A., Korber, B., & Gnanakaran, S. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003046 · Cited by 58
“neutralizing capacity [1–3].”
Seabright, G. E., Cottrell, C. A., van Gils, M. J., D’Addabbo, A., Harvey, D. J., Behrens, A., Allen, J. D., Watanabe, Y., Scaringi, N., Polveroni, T. M., et al. (2020) · Structure · doi:10.1016/j.str.2020.04.022 · Cited by 54
Self-citationCai, H., Orwenyo, J., Giddens, J. P., Yang, Q., Zhang, R., LaBranche, C. C., Montefiori, D. C., & Wang, L.-X. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.005 · Cited by 51
“Previous structural studies have revealed that the two bNAbs, PGT128 and 10-1074, bind to the base of the gp120 V3 loop with a contact of the GDIR motif and interact with the N332 highmannose glycan (Kong et al., 2013; Gristick et al., 2016; Pejchal et al., 2011; Mouquet et al., 2012; Sok et al., 2016).”
InfluentialCD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies
Madani, N., Princiotto, A. M., Schön, A., LaLonde, J. M., Feng, Y., Freire, E., Park, J., Courter, J. R., Jones, D. M., Robinson, J. E., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00540-14 · Cited by 53
Depetris, R. S., Julien, J.-P., Khayat, R., Lee, J. H., Pejchal, R., Katpally, U., Cocco, N., Kachare, M., Massi, E., David, K. B., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.371898 · Cited by 51
“bNAbs in the recently discovered PGT category also have glycan-dependent epitopes (29, 37).”
BackgroundSelf-citationTandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice
Wu, X., Guo, J., Niu, M., An, M., Liu, L., Wang, H., Jin, X., Zhang, Q., Lam, K. S., Wu, T., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96764 · Cited by 50
HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies
Sliepen, K., & Sanders, R. W. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1129905 · Cited by 51
“engineered gp120 outer domain (OD) protein [40] (see below), which was further reduced in size, yielding a scaffolded glycosylated mini-V3 loop.”
BackgroundSelf-citationGautam, R., Nishimura, Y., Lee, W. R., Donau, O. K., Buckler-White, A. J., Shingai, M., Sadjadpour, R., Schmidt, S. D., LaBranche, C. C., Keele, B. F., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00644-12 · Cited by 50
“antibodies (4, 38, 48, 50, 52, 53) using the TZM-bl luciferase reporter gene”
MethodXue, J., Hoorelbeke, B., Kagiampakis, I., Demeler, B., Balzarini, J. M., & LiWang, P. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00332-13 · Cited by 53
Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies
Krumm, S. A., Mohammed, H., Le, K. M., Crispin, M., Wrin, T., Poignard, P., Burton, D. R., & Doores, K. J. (2016) · Retrovirology · doi:10.1186/s12977-016-0241-5 · Cited by 49
“It had been suggested that because the V3 contacts with PGT128 CDRH3 are mainly mediated through backbone hydrogen bonding and van der Waals interactions, as observed in the PGT128-eODmV3 crystal structure, that this interaction is tolerant of side-chain variation [10].”
BackgroundMethodResultInfluentialSelf-citationMengistu, M., Ray, K., Lewis, G. K., & DeVico, A. L. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004772 · Cited by 49
“In gp120, the most broadly reactive domains include the CD4 binding site [22–29], sequences encompassing a high mannose cluster (2G12 [30]) and glycosylated regions of V1V2 loop structures [31–38].”
BackgroundUltrasensitive impedimetric lectin based biosensor for glycoproteins containing sialic acid
Bertók, T., Gemeiner, P., Mikula, M., Gemeiner, P., & Tkáč, J. (2012) · Microchimica Acta · doi:10.1007/s00604-012-0902-6 · Cited by 48
““neutralisation” of HIV viruses [8], more efficient vaccines against autoimmune diseases [9] and a better diagnostics and therapy of various diseases [3].”
Murphy, M. K., Yue, L., Pan, R., Boliar, S., Sethi, A., Jianhui, T., Pfafferott, K. J., Karita, E., Allen, S. A., Cormier, E. G., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003173 · Cited by 53
“from a CRF02_AG elite neutralizer) [6,8], by early plasma nAbs”
BackgroundInfluentialSather, D. N., Carbonetti, S., Kehayia, J., Kraft, Z., Mikell, I., Scheid, J. F., Klein, F., & Stamatatos, L. (2012) · Journal of Virology · doi:10.1128/jvi.01893-12 · Cited by 58
“The breadth of serum cross-neutralizing antibody activities in HIV-1 subjects positively correlates with plasma viral load (8, 23, 31, 32), and recently a number of broadly neutralizing monoclonal antibodies (MAbs) have been isolated from HIV patients, including elite neutralizers (27, 35, 39, 44, 47).”
BackgroundGlycans in Virus-Host Interactions: A Structural Perspective
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.666756 · Cited by 51
Yang, L., Song, Y., Li, X., Huang, X., Liu, J., Ding, H., Zhu, P., & Zhou, P. (2012) · Journal of Virology · doi:10.1128/jvi.07164-11 · Cited by 58
“Man8/9 glycans on gp120 were reported (35, 51).”
BackgroundThe design and evaluation of HIV-1 vaccines
Saunders, K. O., Rudicell, R. S., & Nabel, G. J. (2012) · AIDS · doi:10.1097/qad.0b013e32835474d2 · Cited by 57
“both require an extended CDR H3 that recognizes a conserved glycan and nearby polypeptide [17,93].”
BackgroundThe Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
Thavarajah, J. J., Hønge, B. L., & Wejse, C. M. (2024) · Viruses · doi:10.3390/v16060911 · Cited by 52
“…uniquely capable of penetrating the glycan shield surrounding the surface of HIV-1, enabling them to be tt er bind the conserved epitopes on Env [33]. uniquely capable of penetrating the glycan shield surrounding the surface of HIV-1 enabling them to better bind the conserved epitopes on Env…”
BackgroundXue, J., Gao, Y., Hoorelbeke, B., Kagiampakis, I., Zhao, B., Demeler, B., Balzarini, J., & LiWang, P. J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300194b · Cited by 46
“In fact, it is well-known from antibody research that binding to gp120 does not guarantee an antiviral effect; binding to gp120 can result in potent neutralization of the virus but may also have poor, if any, effect on viral infectivity, depending on the epitope that is recognized on gp120 by these antibodies [64, 65].”
BackgroundSecondary mechanisms of diversification in the human antibody repertoire
Briney, B. S., & Crowe, J. E. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00042 · Cited by 53
West, B. R., Moyer, C. L., King, L., Fusco, M. L., Milligan, J. C., Hui, S., & Saphire, E. O. (2018) · mBio · doi:10.1128/mbio.01674-18 · Cited by 47
The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template
Andrabi, R., Pallesen, J., Allen, J. D., Song, G., Zhang, J., de Val, N., Gegg, G., Porter, K., Su, C.-Y., Pauthner, M. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.082 · Cited by 47
“Binding of one of the V3-N332 epitope-specific bnAbs, PGT128, predominantly relies on the N332 glycan and a neighboring peptide motif (324)GDIR(327) at the base of the V3 loop (Figures 5B and S8) (Garces et al., 2014; Gristick et al., 2016; Kong et al., 2013; Pejchal et al., 2011; Sok et al., 2016b).”
BackgroundSelf-citationKumar, S., Panda, H., Makhdoomi, M. A., Mishra, N., Safdari, H. A., Chawla, H., Aggarwal, H., Reddy, E. S., Lodha, R., Kabra, S. K., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01495-18 · Cited by 46
“earlier for N332 and CD4bs directed adults bNAbs that indels are critical for making contacts 339 with protein or glycans on HIV (47, 48, 55, 56).”
BackgroundInfluentialRapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing
Lieu, R., Antonysamy, S., Druzina, Z., Ho, C., Kang, N. R., Pustilnik, A., Wang, J., & Atwell, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232311 · Cited by 46
“pdb) [20] or as Bence-Jones light chain dimers (e.”
BackgroundPlatt, E. J., Gomes, M. M., & Kabat, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109728109 · Cited by 51
“Concordant with recent evidence that HIV-1 titers are determined by a race between entry of cell-attached virions and competing inactivation processes, we show that NMAb 2G12, which binds to gp120 N-glycans with α (1, 2)linked mannose termini and inhibits replication after passive transfer into patients, neutralizes b…”
BackgroundMethodInfluentialUnprecedented Role of Hybrid N- Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies
Shivatare, V. S., Shivatare, S. S., Lee, C.-C. D., Liang, C. J., Liao, K., Cheng, Y., Saidachary, G., Wu, C., Lin, N., Kwong, P. D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b00896 · Cited by 45
Self-citationHenderson, R. C., Watts, B. E., Ergin, H. N., Anasti, K. M., Parks, R., Xia, S.-M., Trama, A. M., Liao, H., Saunders, K. O., Bonsignori, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08415-7 · Cited by 46
Strategies and Tactics for the Development of Selective Glycan-Binding Proteins
Ward, E. M., Kizer, M. E., & Imperiali, B. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00880 · Cited by 45
Gombos, R. B., Kolodkin‐Gal, D., Eslamizar, L., Owuor, J. O., Mazzola, E., González, A., Korioth-Schmitz, B., Gelman, R. S., Montefiori, D. C., Haynes, B. F., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00783-15 · Cited by 44
Bricault, C. A., Kovacs, J. M., Nkolola, J. P., Yusim, K., Giorgi, E. E., Shields, J. L., Perry, J., Lavine, C. L., Cheung, A., Ellingson-Strouss, K., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03331-14 · Cited by 46
“amino acid sequence motif necessary for the addition of the N332 N-linked glycan (NXS/T), which is important for the V3/glycandependent antibodies (17, 48, 50) (Fig.”
BackgroundLemmin, T., Soto, C. S., Stuckey, J., & Kwong, P. D. (2017) · Structure · doi:10.1016/j.str.2017.07.018 · Cited by 44
HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors
Lin, Y., Parks, K. R., Weidle, C., Naidu, A. S., Khechaduri, A., Riker, A. O., Takushi, B. N., Chun, J.-H., Borst, A. J., Veesler, D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.09.007 · Cited by 45
“The design of 426cOD was based on that of eOD (which was the universal background of derived variants, such as eOD-GT8) (Jardine et al., 2015; Pejchal et al., 2011) (Figure 1A; Table S1).”
MethodSelf-citationNeutralizing Antibodies Targeting HIV-1 gp41
Caillat, C., Guilligay, D., Sulbarán, G., & Weissenhorn, W. (2020) · Viruses · doi:10.3390/v12111210 · Cited by 46
Anti-glycan antibodies: roles in human disease
Temme, J. S., Butler, D. L., & Gildersleeve, J. C. (2021) · Biochemical Journal · doi:10.1042/bcj20200610 · Cited by 48
van den Kerkhof, T. L. G. M., Feenstra, K. A., Euler, Z., van Gils, M. J., Rijsdijk, L. W. E., Boeser‐Nunnink, B., Heringa, J., Schuitemaker, H., & Sanders, R. W. (2013) · Retrovirology · doi:10.1186/1742-4690-10-102 · Cited by 44
“We noted that the glycosylation motif at position 332, which is important for a number of bNAb epitopes [52,59-62,74], is always of the NXS type, and may thus not always be occupied by a glycan.”
InfluentialSelf-citationHIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual
Coss, K. P., Vasiljević, S., Pritchard, L. K., Krumm, S. A., Glaze, M., Madzorera, S. V., Moore, P. L., Crispin, M., & Doores, K. J. (2016) · Journal of Virology · doi:10.1128/jvi.01542-16 · Cited by 42
Self-citationAnthony, C. S., York, T., Bekker, V., Matten, D., Selhorst, P., Ferreria, R.-C., Garrett, N., Karim, S. S. A., Morris, L., Wood, N. T., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00828-17 · Cited by 46
Koch, K., Kalusche, S., Torres, J. L., Stanfield, R. L., Danquah, W., Khazanehdari, K. A., von Briesen, H., Geertsma, E. R., Wilson, I. A., Wernery, U., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08273-7 · Cited by 44
Self-citationStructural basis of broad HIV neutralization by a vaccine-induced cow antibody
Stanfield, R. L., Berndsen, Z. T., Huang, R., Sok, D., Jenkins, G. W., Torres, J. L., Burton, D. R., Ward, A. B., Wilson, I. A., & Smider, V. V. (2020) · Science Advances · doi:10.1126/sciadv.aba0468 · Cited by 46
Self-citationThe Influence of N-Linked Glycans on the Molecular Dynamics of the HIV-1 gp120 V3 Loop
Wood, N. T., Fadda, E., Davis, R., Grant, O. C., Martin, J. C., Woods, R. J., & Travers, S. A. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080301 · Cited by 45
“It has also been shown that N-linked glycans bound to the surface of HIV-1 gp120 form part of several important neutralising antibody epitopes and the removal of even a single glycan can completely abolish a neutralising antibody response [17,19,20].”
BackgroundPritchard, L. K., Spencer, D. I. R., Royle, L., Vasiljević, S., Krumm, S. A., Doores, K. J., & Crispin, M. (2015) · Journal of Virology · doi:10.1128/jvi.00230-15 · Cited by 41
Self-citationSun, M., Pace, C. S., Yao, X., Yu, F. H., Padte, N. N., Huang, Y., Seaman, M. S., Li, Q., & Ho, D. D. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000218 · Cited by 41
Immune Focusing and Enhanced Neutralization Induced by HIV-1 gp140 Chemical Cross-Linking
Schiffner, T., Kong, L., Duncan, C. J. A., Back, J. W., Benschop, J. J., Shen, X., Huang, P., Stewart-Jones, G. B. E., DeStefano, J., Seaman, M. S., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01161-13 · Cited by 45
“, unpublished data) and was produced in HEK293S cells as described previously (39, 40).”
BackgroundMethodSelf-citationNguyen, D. N. P., Xu, B., Stanfield, R. L., Bailey, J. K., Horiya, S., Temme, J. S., Leon, D. R., LaBranche, C. C., Montefiori, D. C., Costello, C. E., et al. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00588 · Cited by 42
Self-citationA cross-neutralizing antibody between HIV-1 and influenza virus
Lee, C.-C. D., Watanabe, Y., Wu, N. C., Han, J., Kumar, S., Pholcharee, T., Seabright, G. E., Allen, J. D., Lin, C.-W., Yang, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009407 · Cited by 43
“2G12 neutralizes HIV-1 by binding to a cluster of high-mannose glycans (mannose patch) on gp120 of Env around a site that is now known as the N332/ V3 base epitope [12,25,26].”
BackgroundSelf-citationPancera, M., Yang, Y., Louder, M. K., Gorman, J., Lu, G., McLellan, J. S., Stuckey, J., Zhu, J., Burton, D. R., Koff, W. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055701 · Cited by 40
“For example, with the PGT130131 subset of PGT125-131 antibodies, the homology modeling indicates the PGT130-131 were as different in mode of recognition from PGT128 as the PGT135-137 (Figure 5); by contrast the functional complementation showed the light chains for PGT130-131 were able to complement the heavy chains o…”
BackgroundMethodSelf-citationKumar, R., Tuen, M., Liu, J., Nadas, A. J., Pan, R., Kong, X., & Hioe, C. E. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.09.010 · Cited by 40
Cai, H., Zhang, R., Orwenyo, J., Giddens, J. P., Yang, Q., LaBranche, C. C., Montefiori, D. C., & Wang, L. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00060 · Cited by 40
Khan, S. N., Sok, D., Tran, K., Movsesyan, A., Dubrovskaya, V., Burton, D. R., & Wyatt, R. T. (2018) · Journal of Virology · doi:10.1128/jvi.00384-18 · Cited by 40
Self-citationBroadly neutralizing antibodies and vaccine design against HIV-1 infection
Wang, Q., & Zhang, L. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0721-9 · Cited by 44
Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity
Joe, C. C. D., Chatterjee, S., Lovrecz, G. O., Adams, T. E., Thaysen‐Andersen, M., Walsh, R., LOCARNINI, S. A., Smooker, P. M., & Netter, H. J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.03.007 · Cited by 42
Pan, R., Sampson, J. M., Chen, Y., Vaine, M., Wang, S., Lu, S., & Kong, X. (2013) · Journal of Virology · doi:10.1128/jvi.00843-13 · Cited by 39
“Interestingly, PGT128 also has a noncanonical disulfide bond between CDRs H1 and H2 that plays a critical role in antigen binding; removing it will make PGT128 lose its gp120-binding activity (40).”
BackgroundSelf-citationTravelling‐wave ion mobility and negative ion fragmentation of high‐mannose N ‐glycans
Harvey, D. J., Scarff, C. A., Edgeworth, M. J., Struwe, W. B., Pagel, K., Thalassinos, K., Crispin, M., & Scrivens, J. H. (2016) · Journal of Mass Spectrometry · doi:10.1002/jms.3738 · Cited by 41
“The spectra of the other two compounds (8, 10) showed a shift of these ions by 162 mass units consistent with the addition of one mannose to the 6-antenna.”
BackgroundMethodInfluentialSelf-citationLongo, N. S., Sutton, M. S., Shiakolas, A. R., Guenaga, J., Jarosinski, M. C., Georgiev, I. S., McKee, K., Bailer, R. T., Louder, M. K., O'Dell, S. J., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01012-16 · Cited by 39
Francica, J. R., Laga, R., Lynn, G. M., Mužíková, G., Androvič, L., Aussedat, B., Walkowicz, W. E., Padhan, K., Ramirez-Valdez, R. A., Parks, R., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000328 · Cited by 40
Kesavardhana, S., & Varadarajan, R. (2014) · Journal of Virology · doi:10.1128/jvi.00494-14 · Cited by 39
Follicular lymphoma and the immune system: from pathogenesis to antibody therapy
Stevenson, F. K., & Stevenson, G. T. (2012) · Blood · doi:10.1182/blood-2011-11-367730 · Cited by 38
Madhavi, V., Wren, L. H., Gonelli, C. A., Winnall, W. R., Parsons, M. S., Kramski, M., Kent, S. J., & Stratov, I. (2014) · AIDS · doi:10.1097/qad.0000000000000310 · Cited by 40
“glycan-dependent epitope) of an immune response, but the relative importance of glycosylation in ADCC recognition of Env is not clear [45,46].”
BackgroundStudying glycobiology at the single-molecule level
Lakshminarayanan, A., Richard, M., & Davis, B. G. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0019-5 · Cited by 40
Cross-reactive broadly neutralizing antibodies: timing is everything
Euler, Z., & Schuitemaker, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00215 · Cited by 43
Li, Y., Xu, S., Ye, Q., Chi, H., Guo, Z., Chen, J., Wu, M. L., Fan, B., Li, B., Qin, C., et al. (2022) · Advanced Science · doi:10.1002/advs.202202689 · Cited by 40
Raška, M., Czerneková, L., Moldoveanu, Z., Zachová, K., Elliott, M. C., Novák, Z., Hall, S. D., Höelscher, M., Maboko, L., Brown, R., et al. (2014) · AIDS Research and Therapy · doi:10.1186/1742-6405-11-23 · Cited by 39
“Although glycans influence protein folding, potentially affecting the conformation of surface-exposed epitopes involved in antibody binding, N-glycans also serve as epitopes or part of epitopes for some broadly neutralizing antibodies [40-54].”
BackgroundMann, A. M., Friedrich, N., Krarup, A., Weber, J., Stiegeler, E., Dreier, B., Pugach, P., Robbiani, M., Riedel, T., Moehle, K., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00152-13 · Cited by 38
“The preference of DARPins for recognizing structural components could be advantageous in selecting HIV envelope-directed inhibitors, particularly as recent findings of potent broadly active neutralizing antibodies revealed a high prevalence of antibodies recognizing conformational inter- and intraprotomer loop-spannin…”
BackgroundIn Silico Methods in Antibody Design
Zhao, J., Nussinov, R., Wu, W., & Ma, B. (2018) · Antibodies · doi:10.3390/antib7030022 · Cited by 40
Glycan-based diagnostic devices: current progress, challenges and perspectives
Wang, S., & Cheng, C. (2015) · Chemical Communications · doi:10.1039/c5cc06876b · Cited by 36
Self-citationRinge, R. P., Phogat, S. K., & Bhattacharya, J. (2012) · Virology · doi:10.1016/j.virol.2012.01.011 · Cited by 40
Simonich, C. A. L., Doepker, L. E., Ralph, D., Williams, J. A., Dhar, A., Yaffe, Z. A., Gentles, L. E., Small, C. T., Oliver, B. G. G., Vigdorovich, V. I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09481-7 · Cited by 37
Antibody responses to the HIV-1 envelope high mannose patch
Daniels, C. N., & Saunders, K. O. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.08.002 · Cited by 36
“The structure of PGT128 in complex with HIV-1 Env gp120 outer domain showed that it interacted with both the N332 and N301 glycans (Pejchal et al., 2011).”
BackgroundInfluentialYuan, T., Li, J., & Zhang, M.-Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069789 · Cited by 47
“For example, bnmAb VRC01 binds to an epitope formed by the CD4 binding site (CD4bs), V5 and loop D (lpD) [11], and bnmAbs PG9/16, CH04 and PGT145 are V1/V2directed antibodies [12], while a short b-strand segment of the V3 loop is involved in binding of PGT127 and 128 to Env trimer [13].”
BackgroundJoyce, M. G., Kanekiyo, M., Xu, L., Biertümpfel, C., Boyington, J. C., Moquin, S. A., Shi, W., Wu, X., Yang, Y., Yang, Z., et al. (2012) · Journal of Virology · doi:10.1128/jvi.02717-12 · Cited by 40
Madani, N., Princiotto, A. M., Easterhoff, D., Bradley, T., Luo, K., Williams, W. B., Liao, H., Moody, M. A., Phad, G. E., Bernat, N. V., et al. (2016) · Journal of Virology · doi:10.1128/jvi.03211-15 · Cited by 35
The Core Fucose on an IgG Antibody is an Endogenous Ligand of Dectin‐1
Manabe, Y., Marchetti, R., Takakura, Y., Nagasaki, M., Nihei, W., Takebe, T., Tanaka, K., Kabayama, K., Chiodo, F., Hanashima, S., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201911875 · Cited by 35
Innovations in HIV-1 Vaccine Design
Jones, L. D., Moody, M. A., & Thompson, A. B. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.01.009 · Cited by 39
Upadhyay, C., Feyznezhad, R., Cao, L., Chan, K.-W., Liu, K., Yang, W., Zhang, H., Yolitz, J., Arthos, J. A., Nadas, A. J., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009185 · Cited by 37
Gao, C., Stavenhagen, K., Eckmair, B., McKitrick, T. R., Mehta, A. Y., Matsumoto, Y., McQuillan, A. M., Hanes, M. S., Eriş, D., Baker, K. J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6834 · Cited by 35
Adolf‐Bryfogle, J., Labonte, J. W., Kraft, J. C., Shapovalov, M. V., Raemisch, S., Lütteke, T., DiMaio, F., Bahl, C. D., Pallesen, J., King, N. P., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011895 · Cited by 36
“Yet, HIV broadly neutralizing antibodies often target glycans as part of their epitopes [3] [4] [5].”
BackgroundSelf-citationChiodo, F., Enríquez‐Navas, P. M., Angulo, J., Marradi, M., & Penadés, S. (2014) · Carbohydrate Research · doi:10.1016/j.carres.2014.07.012 · Cited by 37
Francesconi, O., Nativi, C., Gabrielli, G., Gentili, M., Palchetti, M., Bonora, B., & Roelens, S. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201204298 · Cited by 35
Gianvincenzo, P. D., Calvo, J., Pérez, S., Álvarez, A., Bedoya, L. M., Alcamí, J., & Penadés, S. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00077 · Cited by 35
Precise Structural Analysis of Neutral Glycans Using Aerolysin Mutant T240R Nanopore
Lu, W., Zhao, X., Li, M., Li, Y., Zhang, C., Xiong, Y., Li, J., Zhou, H., Ye, X., Li, X., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01571 · Cited by 35
Epitope target structures of Fc-mediated effector function during HIV-1 acquisition
Lewis, G. K., Guan, Y., Kamin‐Lewis, R., Sajadi, M. M., Pazgier, M., & DeVico, A. L. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000055 · Cited by 34
Toonstra, C., Amin, M. A., & Wang, L. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b01044 · Cited by 36
Pantophlet, R. A., Trattnig, N., Murrell, S., Lu, N., Chau, D., Rempel, C., Wilson, I. A., & Kosma, P. (2017) · Nature Communications · doi:10.1038/s41467-017-01640-y · Cited by 34
Self-citationJia, M., Liberatore, R. A., Guo, Y., Chan, K., Pan, R., Lü, H., Waltari, E., Mittler, E., Chandran, K., Finzi, A., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.024 · Cited by 39
Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
Mannar, D., Leopold, K., & Subramaniam, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-91746-7 · Cited by 34
“Antibodies All anti-gp120 IgG antibodies were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (2G12) from Polymun Scientific, Anti-HIV-1 gp120 Monoclonal (PG9) from IAVI (cat# 12149), Anti-HIV-1 gp120 Monoclonal (PG16) from IAVI, Anti-HIV-1 gp120 Monoclonal (PGT…”
BackgroundComparing domain interactions within antibody Fabs with kappa and lambda light chains
Toughiri, R., Wu, X., Ruiz, D. I., Huang, F., Crissman, J. W., Dickey, M., Froning, K., Conner, E. M., Cujec, T. P., & Demarest, S. J. (2016) · mAbs · doi:10.1080/19420862.2016.1214785 · Cited by 34
Hake, A., & Pfeifer, N. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005789 · Cited by 34
Pape, C., Remme, R., Wolny, A., Olberg, S., Wolf, S., Cerrone, L., Cortese, M., Klaus, S., Lucic, B., Ullrich, S., et al. (2020) · BioEssays · doi:10.1002/bies.202000257 · Cited by 38
“Alterations in post-translational modifications are likely to influence the ability of serum antibodies to bind to different viral epitopes as it was shown for other viruses such as HIV-1.[41] It has to be noted that the detection of viral RNA requires fixation and permeabilization of cells, which has the potential to…”
BackgroundStructural Plasticity of the Semliki Forest Virus Glycome upon Interspecies Transmission
Crispin, M., Harvey, D. J., Bitto, D., Bonomelli, C., Edgeworth, M. J., Scrivens, J. H., Huiskonen, J. T., & Bowden, T. A. (2014) · Journal of Proteome Research · doi:10.1021/pr401162k · Cited by 36
Self-citationPatil, S. A., Kumar, R., Deshpande, S., Samal, S., Shrivastava, T., Boliar, S., Bansal, M., Chaudhary, N. K., Srikrishnan, A. K., Murugavel, K. G., et al. (2016) · Journal of Virology · doi:10.1128/jvi.03090-15 · Cited by 33
Passive and active antibody studies in primates to inform HIV vaccines
Hessell, A. J., Malherbe, D. C., & Haigwood, N. L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1425619 · Cited by 33
“[19]) that have been associated with critical protein or glycan contacts [13,17].”
BackgroundLi, S. W., Yu, B., Byrne, G., Wright, M., O’Rourke, S. M., Mesa, K. A., & Berman, P. W. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27016 · Cited by 33
Restricted N-glycan Conformational Space in the PDB and Its Implication in Glycan Structure Modeling
Jo, S., Lee, H. S., Skolnick, J., & Im, W. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002946 · Cited by 36
Rathore, U., Saha, P., Kesavardhana, S., Kumar, A. A., Datta, R., Sankar, D. S., Das, R., Mascola, J. R., & Varadarajan, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.788919 · Cited by 36
Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens
Schiffner, T., de Val, N., Russell, R. A., de Taeye, S. W., de la Peña, A. T., Ozorowski, G., Kim, H. J., Nieusma, T., Brod, F., Cupo, A., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01942-15 · Cited by 32
Self-citation
Metadata
- Authors
- Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C.-H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- University of Washington (US)
- University of Oxford (GB)
- Cornell University (US)
- Progenics Pharmaceuticals (United States) (US)
- National Institutes of Health (US)
- Imperial College London (GB)
- Japan Science and Technology Agency (JP)
- Corresponding author
- Pejchal, Robert
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Burton, Dennis R.
- Wilson, Ian A.
- ORCID
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Wang, Sheng-Kai
- Stanfield, Robyn L.
- Julien, Jean-Philippe
- Crispin, Max
- Depetris, Rafael
- Cupo, Albert
- Liu, Yan
- McBride, Ryan
- Ito, Yukishige
- Sanders, Rogier W.
- Paulson, James C.
- Feizi, Ten
- Wong, Chi-Huey
- Moore, John P.
- Olson, William C.
- Ward, Andrew B.
- Poignard, Pascal
- Schief, William R.
- Burton, Dennis R.
- Wilson, Ian A.
- Venue
- Science
- Published
- 2011-11-25
- Volume
- 334
- Issue
- 6059
- Pages
- 1097-1103
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3280215
- OpenAlex
- W2128579789
- Cited by
- 694
- References
- 75
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 18 · 2023: 19 · 2022: 25 · 2021: 35 · 2020: 34 · 2019: 37 · 2018: 54 · 2017: 54 · 2016: 62 · 2015: 70 · 2014: 69 · 2013: 105 · 2012: 72
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Canadian Institutes of Health Research (HFE-224662)
- Engineering and Physical Sciences Research Council (EP/G037604/1, GR/S79268/02)
- National Cancer Institute (Y1-CO-1020, U01CA128416)
- National Institute of General Medical Sciences (Y1-GM-1104)
- National Institute of Allergy and Infectious Diseases (AI-33292, F32AI074372, AI74372, R37AI033292, R56AI084817, P01AI082362, AI082362, R01AI033292, R01AI084817, AI84817)
- National Center for Research Resources (P41RR001209, RR017573, P41RR017573)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1, broadly neutralizing antibodies, gp120, glycan shield, V3 loop, antibody penetration
- MeSH terms
- Antibody Specificity, Epitopes, Binding Sites, Antibody, Carbohydrate Conformation, Cell Line, Disaccharides, Glycosylation, Humans, Hydrogen Bonding, Immunoglobulin Fab Fragments, Mannose, Mannosides, Models, Molecular, Mutation, Oligosaccharides, Polysaccharides, Protein Conformation, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, Protein Structure, Tertiary, Crystallography, X-Ray, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.